<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%) </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar) in insulin-na√Øve subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> inadequately controlled with oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In this 16-week, open-label trial, subjects (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m(2)) were randomized to once-daily IDegAsp (n = 59), AF (n = 59), or IGlar (n = 60), <z:hpo ids='HP_0000001'>all</z:hpo> in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin was administered before the evening meal and dose-titrated to a fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) target of 4.0-6.0 mmol/L </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After 16 weeks, mean A1C decreased in <z:hpo ids='HP_0000001'>all</z:hpo> groups to comparable levels (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%) </plain></SENT>
<SENT sid="5" pm="."><plain>A similar proportion of subjects achieved A1C &lt;7.0% without confirmed <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in the last 4 weeks of treatment (IDegAsp: 51%; AF: 47%; IGlar: 50%) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean 2-h postdinner plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> increase was lower for IDegAsp (0.13 mmol/L) and AF (0.24 mmol/L) than IGlar (1.63 mmol/L), whereas mean FPG was similar (IDegAsp: 6.8 mmol/L; AF: 7.4 mmol/L; IGlar: 7.0 mmol/L) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> rates were lower for IDegAsp and IGlar than AF (1.2, 0.7, and 2.4 events/patient year) </plain></SENT>
<SENT sid="8" pm="."><plain>Nocturnal hypoglycemic events occurred rarely for IDegAsp (1 event) and IGlar (3 events) compared with AF (27 events) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, but better postdinner plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
</text></document>